Intravenous Urokinase in Acute Myocardial Infarction
Summary Two noncomparative multicentre studies investigated the clinical efficacy and tolerability of urokinase in patients with acute myocardial infarction. In a preliminary study in 364 patients, the mortality rate was 7.4% during the 2-week period after infusion with urokinase 2.1 million units o...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Masini, Giuseppe [verfasserIn] Innocenti, Paolo [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1991 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Clinical drug investigation - Berlin [u.a.] : Springer, 1989, 3(1991), 5 vom: Okt., Seite 368-373 |
|---|---|
| Übergeordnetes Werk: |
volume:3 ; year:1991 ; number:5 ; month:10 ; pages:368-373 |
| Links: |
|---|
| DOI / URN: |
10.1007/BF03259755 |
|---|
| Katalog-ID: |
SPR032995822 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR032995822 | ||
| 003 | DE-627 | ||
| 005 | 20230519200748.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s1991 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/BF03259755 |2 doi | |
| 035 | |a (DE-627)SPR032995822 | ||
| 035 | |a (SPR)BF03259755-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Masini, Giuseppe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intravenous Urokinase in Acute Myocardial Infarction |
| 264 | 1 | |c 1991 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Summary Two noncomparative multicentre studies investigated the clinical efficacy and tolerability of urokinase in patients with acute myocardial infarction. In a preliminary study in 364 patients, the mortality rate was 7.4% during the 2-week period after infusion with urokinase 2.1 million units over about 24 hours compared with a lower value of 4.4% in the main study in 634 patients over the same period, but after infusion with urokinase 2 million units over less than 3.25 hours. In both the preliminary and main studies, there was a low incidence of adverse effects (4.9% vs 3.2% of patients, respectively) and, in particular, of major bleeding complications. Global tolerability was considered good or very good in 95% of patients in the main study. Thus, the intravenous infusion of urokinase 2 million units over < 3.25 hours offers high therapeutic activity together with excellent tolerability. | ||
| 650 | 4 | |a Acute Myocardial Infarction |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Urokinase |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Acute Myocardial Infarction |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Streptokinase |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Main Study |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Innocenti, Paolo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical drug investigation |d Berlin [u.a.] : Springer, 1989 |g 3(1991), 5 vom: Okt., Seite 368-373 |w (DE-627)327645083 |w (DE-600)2043793-6 |x 1179-1918 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:1991 |g number:5 |g month:10 |g pages:368-373 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/BF03259755 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2190 | ||
| 936 | b | k | |a 44.40 |q ASE |
| 951 | |a AR | ||
| 952 | |d 3 |j 1991 |e 5 |c 10 |h 368-373 | ||
| author_variant |
g m gm p i pi |
|---|---|
| matchkey_str |
article:11791918:1991----::nrvnuuoiaenctmoa |
| hierarchy_sort_str |
1991 |
| bklnumber |
44.40 |
| publishDate |
1991 |
| allfields |
10.1007/BF03259755 doi (DE-627)SPR032995822 (SPR)BF03259755-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Masini, Giuseppe verfasserin aut Intravenous Urokinase in Acute Myocardial Infarction 1991 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Two noncomparative multicentre studies investigated the clinical efficacy and tolerability of urokinase in patients with acute myocardial infarction. In a preliminary study in 364 patients, the mortality rate was 7.4% during the 2-week period after infusion with urokinase 2.1 million units over about 24 hours compared with a lower value of 4.4% in the main study in 634 patients over the same period, but after infusion with urokinase 2 million units over less than 3.25 hours. In both the preliminary and main studies, there was a low incidence of adverse effects (4.9% vs 3.2% of patients, respectively) and, in particular, of major bleeding complications. Global tolerability was considered good or very good in 95% of patients in the main study. Thus, the intravenous infusion of urokinase 2 million units over < 3.25 hours offers high therapeutic activity together with excellent tolerability. Acute Myocardial Infarction (dpeaa)DE-He213 Urokinase (dpeaa)DE-He213 Acute Myocardial Infarction (dpeaa)DE-He213 Streptokinase (dpeaa)DE-He213 Main Study (dpeaa)DE-He213 Innocenti, Paolo verfasserin aut Enthalten in Clinical drug investigation Berlin [u.a.] : Springer, 1989 3(1991), 5 vom: Okt., Seite 368-373 (DE-627)327645083 (DE-600)2043793-6 1179-1918 nnns volume:3 year:1991 number:5 month:10 pages:368-373 https://dx.doi.org/10.1007/BF03259755 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 3 1991 5 10 368-373 |
| spelling |
10.1007/BF03259755 doi (DE-627)SPR032995822 (SPR)BF03259755-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Masini, Giuseppe verfasserin aut Intravenous Urokinase in Acute Myocardial Infarction 1991 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Two noncomparative multicentre studies investigated the clinical efficacy and tolerability of urokinase in patients with acute myocardial infarction. In a preliminary study in 364 patients, the mortality rate was 7.4% during the 2-week period after infusion with urokinase 2.1 million units over about 24 hours compared with a lower value of 4.4% in the main study in 634 patients over the same period, but after infusion with urokinase 2 million units over less than 3.25 hours. In both the preliminary and main studies, there was a low incidence of adverse effects (4.9% vs 3.2% of patients, respectively) and, in particular, of major bleeding complications. Global tolerability was considered good or very good in 95% of patients in the main study. Thus, the intravenous infusion of urokinase 2 million units over < 3.25 hours offers high therapeutic activity together with excellent tolerability. Acute Myocardial Infarction (dpeaa)DE-He213 Urokinase (dpeaa)DE-He213 Acute Myocardial Infarction (dpeaa)DE-He213 Streptokinase (dpeaa)DE-He213 Main Study (dpeaa)DE-He213 Innocenti, Paolo verfasserin aut Enthalten in Clinical drug investigation Berlin [u.a.] : Springer, 1989 3(1991), 5 vom: Okt., Seite 368-373 (DE-627)327645083 (DE-600)2043793-6 1179-1918 nnns volume:3 year:1991 number:5 month:10 pages:368-373 https://dx.doi.org/10.1007/BF03259755 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 3 1991 5 10 368-373 |
| allfields_unstemmed |
10.1007/BF03259755 doi (DE-627)SPR032995822 (SPR)BF03259755-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Masini, Giuseppe verfasserin aut Intravenous Urokinase in Acute Myocardial Infarction 1991 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Two noncomparative multicentre studies investigated the clinical efficacy and tolerability of urokinase in patients with acute myocardial infarction. In a preliminary study in 364 patients, the mortality rate was 7.4% during the 2-week period after infusion with urokinase 2.1 million units over about 24 hours compared with a lower value of 4.4% in the main study in 634 patients over the same period, but after infusion with urokinase 2 million units over less than 3.25 hours. In both the preliminary and main studies, there was a low incidence of adverse effects (4.9% vs 3.2% of patients, respectively) and, in particular, of major bleeding complications. Global tolerability was considered good or very good in 95% of patients in the main study. Thus, the intravenous infusion of urokinase 2 million units over < 3.25 hours offers high therapeutic activity together with excellent tolerability. Acute Myocardial Infarction (dpeaa)DE-He213 Urokinase (dpeaa)DE-He213 Acute Myocardial Infarction (dpeaa)DE-He213 Streptokinase (dpeaa)DE-He213 Main Study (dpeaa)DE-He213 Innocenti, Paolo verfasserin aut Enthalten in Clinical drug investigation Berlin [u.a.] : Springer, 1989 3(1991), 5 vom: Okt., Seite 368-373 (DE-627)327645083 (DE-600)2043793-6 1179-1918 nnns volume:3 year:1991 number:5 month:10 pages:368-373 https://dx.doi.org/10.1007/BF03259755 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 3 1991 5 10 368-373 |
| allfieldsGer |
10.1007/BF03259755 doi (DE-627)SPR032995822 (SPR)BF03259755-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Masini, Giuseppe verfasserin aut Intravenous Urokinase in Acute Myocardial Infarction 1991 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Two noncomparative multicentre studies investigated the clinical efficacy and tolerability of urokinase in patients with acute myocardial infarction. In a preliminary study in 364 patients, the mortality rate was 7.4% during the 2-week period after infusion with urokinase 2.1 million units over about 24 hours compared with a lower value of 4.4% in the main study in 634 patients over the same period, but after infusion with urokinase 2 million units over less than 3.25 hours. In both the preliminary and main studies, there was a low incidence of adverse effects (4.9% vs 3.2% of patients, respectively) and, in particular, of major bleeding complications. Global tolerability was considered good or very good in 95% of patients in the main study. Thus, the intravenous infusion of urokinase 2 million units over < 3.25 hours offers high therapeutic activity together with excellent tolerability. Acute Myocardial Infarction (dpeaa)DE-He213 Urokinase (dpeaa)DE-He213 Acute Myocardial Infarction (dpeaa)DE-He213 Streptokinase (dpeaa)DE-He213 Main Study (dpeaa)DE-He213 Innocenti, Paolo verfasserin aut Enthalten in Clinical drug investigation Berlin [u.a.] : Springer, 1989 3(1991), 5 vom: Okt., Seite 368-373 (DE-627)327645083 (DE-600)2043793-6 1179-1918 nnns volume:3 year:1991 number:5 month:10 pages:368-373 https://dx.doi.org/10.1007/BF03259755 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 3 1991 5 10 368-373 |
| allfieldsSound |
10.1007/BF03259755 doi (DE-627)SPR032995822 (SPR)BF03259755-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Masini, Giuseppe verfasserin aut Intravenous Urokinase in Acute Myocardial Infarction 1991 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Two noncomparative multicentre studies investigated the clinical efficacy and tolerability of urokinase in patients with acute myocardial infarction. In a preliminary study in 364 patients, the mortality rate was 7.4% during the 2-week period after infusion with urokinase 2.1 million units over about 24 hours compared with a lower value of 4.4% in the main study in 634 patients over the same period, but after infusion with urokinase 2 million units over less than 3.25 hours. In both the preliminary and main studies, there was a low incidence of adverse effects (4.9% vs 3.2% of patients, respectively) and, in particular, of major bleeding complications. Global tolerability was considered good or very good in 95% of patients in the main study. Thus, the intravenous infusion of urokinase 2 million units over < 3.25 hours offers high therapeutic activity together with excellent tolerability. Acute Myocardial Infarction (dpeaa)DE-He213 Urokinase (dpeaa)DE-He213 Acute Myocardial Infarction (dpeaa)DE-He213 Streptokinase (dpeaa)DE-He213 Main Study (dpeaa)DE-He213 Innocenti, Paolo verfasserin aut Enthalten in Clinical drug investigation Berlin [u.a.] : Springer, 1989 3(1991), 5 vom: Okt., Seite 368-373 (DE-627)327645083 (DE-600)2043793-6 1179-1918 nnns volume:3 year:1991 number:5 month:10 pages:368-373 https://dx.doi.org/10.1007/BF03259755 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 3 1991 5 10 368-373 |
| language |
English |
| source |
Enthalten in Clinical drug investigation 3(1991), 5 vom: Okt., Seite 368-373 volume:3 year:1991 number:5 month:10 pages:368-373 |
| sourceStr |
Enthalten in Clinical drug investigation 3(1991), 5 vom: Okt., Seite 368-373 volume:3 year:1991 number:5 month:10 pages:368-373 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Acute Myocardial Infarction Urokinase Streptokinase Main Study |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Clinical drug investigation |
| authorswithroles_txt_mv |
Masini, Giuseppe @@aut@@ Innocenti, Paolo @@aut@@ |
| publishDateDaySort_date |
1991-10-01T00:00:00Z |
| hierarchy_top_id |
327645083 |
| dewey-sort |
3610 |
| id |
SPR032995822 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR032995822</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519200748.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1991 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/BF03259755</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR032995822</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)BF03259755-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Masini, Giuseppe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Intravenous Urokinase in Acute Myocardial Infarction</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1991</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Two noncomparative multicentre studies investigated the clinical efficacy and tolerability of urokinase in patients with acute myocardial infarction. In a preliminary study in 364 patients, the mortality rate was 7.4% during the 2-week period after infusion with urokinase 2.1 million units over about 24 hours compared with a lower value of 4.4% in the main study in 634 patients over the same period, but after infusion with urokinase 2 million units over less than 3.25 hours. In both the preliminary and main studies, there was a low incidence of adverse effects (4.9% vs 3.2% of patients, respectively) and, in particular, of major bleeding complications. Global tolerability was considered good or very good in 95% of patients in the main study. Thus, the intravenous infusion of urokinase 2 million units over < 3.25 hours offers high therapeutic activity together with excellent tolerability.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Acute Myocardial Infarction</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Urokinase</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Acute Myocardial Infarction</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Streptokinase</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Main Study</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Innocenti, Paolo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Clinical drug investigation</subfield><subfield code="d">Berlin [u.a.] : Springer, 1989</subfield><subfield code="g">3(1991), 5 vom: Okt., Seite 368-373</subfield><subfield code="w">(DE-627)327645083</subfield><subfield code="w">(DE-600)2043793-6</subfield><subfield code="x">1179-1918</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:3</subfield><subfield code="g">year:1991</subfield><subfield code="g">number:5</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:368-373</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/BF03259755</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">3</subfield><subfield code="j">1991</subfield><subfield code="e">5</subfield><subfield code="c">10</subfield><subfield code="h">368-373</subfield></datafield></record></collection>
|
| author |
Masini, Giuseppe |
| spellingShingle |
Masini, Giuseppe ddc 610 bkl 44.40 misc Acute Myocardial Infarction misc Urokinase misc Streptokinase misc Main Study Intravenous Urokinase in Acute Myocardial Infarction |
| authorStr |
Masini, Giuseppe |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)327645083 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1179-1918 |
| topic_title |
610 ASE 44.40 bkl Intravenous Urokinase in Acute Myocardial Infarction Acute Myocardial Infarction (dpeaa)DE-He213 Urokinase (dpeaa)DE-He213 Streptokinase (dpeaa)DE-He213 Main Study (dpeaa)DE-He213 |
| topic |
ddc 610 bkl 44.40 misc Acute Myocardial Infarction misc Urokinase misc Streptokinase misc Main Study |
| topic_unstemmed |
ddc 610 bkl 44.40 misc Acute Myocardial Infarction misc Urokinase misc Streptokinase misc Main Study |
| topic_browse |
ddc 610 bkl 44.40 misc Acute Myocardial Infarction misc Urokinase misc Streptokinase misc Main Study |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Clinical drug investigation |
| hierarchy_parent_id |
327645083 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Clinical drug investigation |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)327645083 (DE-600)2043793-6 |
| title |
Intravenous Urokinase in Acute Myocardial Infarction |
| ctrlnum |
(DE-627)SPR032995822 (SPR)BF03259755-e |
| title_full |
Intravenous Urokinase in Acute Myocardial Infarction |
| author_sort |
Masini, Giuseppe |
| journal |
Clinical drug investigation |
| journalStr |
Clinical drug investigation |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
1991 |
| contenttype_str_mv |
txt |
| container_start_page |
368 |
| author_browse |
Masini, Giuseppe Innocenti, Paolo |
| container_volume |
3 |
| class |
610 ASE 44.40 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Masini, Giuseppe |
| doi_str_mv |
10.1007/BF03259755 |
| dewey-full |
610 |
| author2-role |
verfasserin |
| title_sort |
intravenous urokinase in acute myocardial infarction |
| title_auth |
Intravenous Urokinase in Acute Myocardial Infarction |
| abstract |
Summary Two noncomparative multicentre studies investigated the clinical efficacy and tolerability of urokinase in patients with acute myocardial infarction. In a preliminary study in 364 patients, the mortality rate was 7.4% during the 2-week period after infusion with urokinase 2.1 million units over about 24 hours compared with a lower value of 4.4% in the main study in 634 patients over the same period, but after infusion with urokinase 2 million units over less than 3.25 hours. In both the preliminary and main studies, there was a low incidence of adverse effects (4.9% vs 3.2% of patients, respectively) and, in particular, of major bleeding complications. Global tolerability was considered good or very good in 95% of patients in the main study. Thus, the intravenous infusion of urokinase 2 million units over < 3.25 hours offers high therapeutic activity together with excellent tolerability. |
| abstractGer |
Summary Two noncomparative multicentre studies investigated the clinical efficacy and tolerability of urokinase in patients with acute myocardial infarction. In a preliminary study in 364 patients, the mortality rate was 7.4% during the 2-week period after infusion with urokinase 2.1 million units over about 24 hours compared with a lower value of 4.4% in the main study in 634 patients over the same period, but after infusion with urokinase 2 million units over less than 3.25 hours. In both the preliminary and main studies, there was a low incidence of adverse effects (4.9% vs 3.2% of patients, respectively) and, in particular, of major bleeding complications. Global tolerability was considered good or very good in 95% of patients in the main study. Thus, the intravenous infusion of urokinase 2 million units over < 3.25 hours offers high therapeutic activity together with excellent tolerability. |
| abstract_unstemmed |
Summary Two noncomparative multicentre studies investigated the clinical efficacy and tolerability of urokinase in patients with acute myocardial infarction. In a preliminary study in 364 patients, the mortality rate was 7.4% during the 2-week period after infusion with urokinase 2.1 million units over about 24 hours compared with a lower value of 4.4% in the main study in 634 patients over the same period, but after infusion with urokinase 2 million units over less than 3.25 hours. In both the preliminary and main studies, there was a low incidence of adverse effects (4.9% vs 3.2% of patients, respectively) and, in particular, of major bleeding complications. Global tolerability was considered good or very good in 95% of patients in the main study. Thus, the intravenous infusion of urokinase 2 million units over < 3.25 hours offers high therapeutic activity together with excellent tolerability. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 |
| container_issue |
5 |
| title_short |
Intravenous Urokinase in Acute Myocardial Infarction |
| url |
https://dx.doi.org/10.1007/BF03259755 |
| remote_bool |
true |
| author2 |
Innocenti, Paolo |
| author2Str |
Innocenti, Paolo |
| ppnlink |
327645083 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/BF03259755 |
| up_date |
2024-07-03T15:56:41.397Z |
| _version_ |
1803573999849963520 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR032995822</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519200748.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1991 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/BF03259755</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR032995822</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)BF03259755-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Masini, Giuseppe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Intravenous Urokinase in Acute Myocardial Infarction</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1991</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Two noncomparative multicentre studies investigated the clinical efficacy and tolerability of urokinase in patients with acute myocardial infarction. In a preliminary study in 364 patients, the mortality rate was 7.4% during the 2-week period after infusion with urokinase 2.1 million units over about 24 hours compared with a lower value of 4.4% in the main study in 634 patients over the same period, but after infusion with urokinase 2 million units over less than 3.25 hours. In both the preliminary and main studies, there was a low incidence of adverse effects (4.9% vs 3.2% of patients, respectively) and, in particular, of major bleeding complications. Global tolerability was considered good or very good in 95% of patients in the main study. Thus, the intravenous infusion of urokinase 2 million units over < 3.25 hours offers high therapeutic activity together with excellent tolerability.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Acute Myocardial Infarction</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Urokinase</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Acute Myocardial Infarction</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Streptokinase</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Main Study</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Innocenti, Paolo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Clinical drug investigation</subfield><subfield code="d">Berlin [u.a.] : Springer, 1989</subfield><subfield code="g">3(1991), 5 vom: Okt., Seite 368-373</subfield><subfield code="w">(DE-627)327645083</subfield><subfield code="w">(DE-600)2043793-6</subfield><subfield code="x">1179-1918</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:3</subfield><subfield code="g">year:1991</subfield><subfield code="g">number:5</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:368-373</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/BF03259755</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">3</subfield><subfield code="j">1991</subfield><subfield code="e">5</subfield><subfield code="c">10</subfield><subfield code="h">368-373</subfield></datafield></record></collection>
|
| score |
7.4005966 |